Company intelligence / Profile preview

Scandipharm

Birmingham, Alabama, United States

Ownership: Private
Development stage: Other

Overview

Scandipharm was a specialty pharmaceutical company primarily focused on developing and marketing therapies for cystic fibrosis and gastrointestinal disorders. The company was well-known for its portfolio of pancreatic enzyme replacement therapies and specialized vitamin supplements designed for patients with malabsorption issues. Its flagship products included Ultrase and Viokase, which are used to treat exocrine pancreatic insufficiency. Scandipharm was acquired by Axcan Pharma in 1999, which significantly expanded Axcan's presence in the North American gastroenterology market.

Therapeutic areas: GastroenterologyPulmonology
Modalities: BiologicSmall moleculeAnimal-extracted protein clinical productsPancreatic enzymes
Industry: Biotech

Beyond the preview

Go deeper on Scandipharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scandipharm.

Explore the full profile